H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Neutral rating and $60.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

The analyst commented: "VOXZOGO's ~85% U.S. retention keeps us cautious as oral competition could arrive before hypochondroplasia adds revenue. BioMarin reported 3Q26 revenue of $1.025B (+3.5% Q/Q), including $245M from VOXZOGO (-3% Q/Q), and lowered 2026 VOXZOGO (vosoritide) guidance to $975M-$1.025B from $1.0-1.05B. Management attributed the revision to international shipment timing and still expects VOXZOGO growth in 2027. International expansion, its labeled-age edge in children under two, and a potential hypochondroplasia (HCH) launch support that outlook. However, BridgeBio's (BBIO; Buy; Selvaraju) oral infigratinib has a February 4, 2027 FDA action date, nearly four months before VOXZOGO's May 30 HCH decision, creating the potential for additional achondroplasia (ACH) competition before HCH contributes (Exhibit 2). Amicus' $201M quarterly contribution and YUVIWEL royalties provide offsets, but VOXZOGO's daily injection burden remains an in-market drawback. We reiterate our Neutral rating and 12-month price target of $60 per share."

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $55.66 yesterday.

You May Also Be Interested In

• Jefferies on ArcBest (ARCB): 'The quarter was a solid beat' (correction)
• Citi reiterates Buy rating on Circle Internet Group with $243 target
• Anixa ovarian cancer CAR-T trial data to be presented in London